-
How to treat childhood leukemia, how to use this anti-cancer drug?
Time of Update: 2022-09-15
Let's talk brieflyHow to apply it to children?For the dose of vincristine, it is recommended that pediatric intravenous injection be given once per body weight of 0.
-
What are the cardiotoxicities of immunotherapy? How is it treated?
Time of Update: 2022-09-15
1Clinical manifestations of ICI-associated cardiotoxicityCurrently, ICI clinical trial results and current clinical practice reports suggest multiple manifestations of ICI-associated cardiotoxicity, such as myocarditis, pericardial disease, arrhythmias, myocardial infarction, and even non-inflammatory left ventricular dysfunction such as Tako-Tsubo cardiomyopathy [1] (Figure 1).
-
JAMA Sub-Journal: Which patients with advanced gastroesophageal cancer benefit from immunotherapy?
Time of Update: 2022-09-15
A study from a sub-journal of JAMA showed that tissue-based PD-L1 expression in patients with aGEC was more certain of the benefits of ICI-containing treatment to varying degrees than with standard therapy (SOC).
-
JAMA (IF=157) Breaks the rules! Ma Jun's team at Sun Yat-sen University found that the use of intensity-modulated radiation alone for low-risk nasopharyngeal carcinoma patients was no less effective than that of simultaneous chemoradiation
Time of Update: 2022-09-15
" Low-risk Nasopharyngeal Carcinoma, A Randomized Clinical Trial" research paper, this multicenter, open-label, randomized, Phase 3, non-inferiority clinical trial conducted in 5 Chinese hospitals, including 341 adult patients with low-risk NPC, defined as Phase II/T3N0M0, with no adverse features, enrollment period from November 2015 to August 2020。 The last follow-up date was March 15, 2022.
-
In August, this new anti-cancer drug was approved for marketing!
Time of Update: 2022-09-15
The approved indications are "for adult patients with newly diagnosed CD20-positive diffuse large B-cell non-Hodgkin lymphoma (DLBCL) with an International Prognostic Index (IPI) of 0-2 points, and should be treated in combination with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone).
-
Professor Ma Jun: Hematological tumor patients are at high risk of severe COVID-19 and need to be comprehensively prevented
Time of Update: 2022-09-15
Professor Ma Jun, director of the Harbin Institute of Hematology and Oncology, told reporters that blood tumors are mainly divided into four types, one is lymphoma, the incidence rate ranks first, and the annual new cases in China are about 120,000; The second is leukemia, with about 100,000 new cases every year; The third is multiple myeloma, with about 80,000 new cases per year; The fourth is the syndrome of myelodysplastic abnormalities, with about 80,000 new cases per year.
-
7 years, more than that! SOLO-1 research OS data debuted at ESMO - Orapali "maintained" long survival, the prospect is promising
Time of Update: 2022-09-15
Professor Kong Beihua stressed that in the study, the survival benefits of Olaparelli can continue for a long time after 2 years of treatment, which makes BRCAm patients with advanced ovarian cancer see the hope of receiving a "clinical cure" after standard surgery and chemotherapy and then receiving standardized first-line maintenance therapy.
-
Practice-oriented, "move" the road to peers! ASCT Transplantation Scholar Ceremony - ASCT HOW came to a successful conclusion
Time of Update: 2022-09-15
"Move" the road together, although far will reach! Sponsored by the Hematology and Oncology Committee of the Chinese Anti-Cancer Association (CACA), the Autologous Hematopoietic Stem Cell Transplantat
-
Adaptive immune resistance to AIR at tumor sites: mechanisms and future prospects
Time of Update: 2022-09-15
However, immunotherapy methods based on enhancing the T cell-mediated immune response against antigens (collectively referred to as "immune enhancers") often face similar problems to other conventional cancer treatments, such as limited efficacy and high toxicity 。 PD-1/PD-L1-blocked immunotherapy has been successfully applied to clinical patients, and since pembrolizumab and nivolumab were approved for advanced melanoma in 2014, the FDA has approved multiple indications for up to 20 solid tumors or hematologic malignancies of PD-1/PD-L1 monoclonal antibody.
-
[BMJ] Two major studies of ultra-processed foods are associated with both high-risk colon cancer and higher-risk heart disease deaths
Time of Update: 2022-09-15
The researchers say there is no link between ultra-processed foods and women's risk of colon cancer, and the underlying cause is unclear.
The researchers say there is no link between ultra-processed foods and women's risk of colon cancer, and the underlying cause is unclear.
-
Prof. Zhang Wei & Prof. Wenyu Li: Otolizumab brings clinical benefits to patients with limbic lymphoma, and the future can be expected!
Time of Update: 2022-09-15
Limbic lymphoma (MZL) is a group of B-cell lymphomas that originate in the marginal region of lymph follicles and can occur in the splenic, lymph node, and mucosal lymphoid tissue. MZL includes three
-
Frontier Ovarian cancer recurrence-free survival is extended by more than 3 times, and this gene helps personalized cancer treatment
Time of Update: 2022-09-15
▲If you have any business needs, please long press to scan the QR code above, or▎ WuXi AppTec content team editorAs an invisible killer of women's health, the early symptoms of ovarian cancer are not obvious, and most patients are diagnosed at an advanced stage, missing the golden period of early intervention and the prognosis is not good.
-
The same is the third generation of targeted drugs for lung cancer, can one drug be reversed after another?
Time of Update: 2022-09-15
revelationIn the above case, after the patient used osimitinib resistance, the patient was relieved and benefited from the use of vometinib, which is also a third-generation targeted drug, in large doses.
-
i Hope Time Professor Xiaoling Liu: Reflections on Immunotherapy for Biliary Tumors
Time of Update: 2022-09-15
The TOPAZ-1 study is a randomized, double-blind, placebo-controlled, global multicenter phase III clinical trial to evaluate the efficacy and safety of duvalliumab plus standard chemotherapy versus placebo-plus chemotherapy as a first-line treatment for advanced biliary system tumors (BTC).
-
Important picture: Partitioning of mediastinal lymph nodes
Time of Update: 2022-09-14
Upper boundary: upper edge of sternal stem, lower boundary: tracheal protrusionIASLC map(4)Lymph nodes in group 4 (lower paratracheal) are similar to those in group 2, also located around the trachea, but on the caudal side of the aortic arch plane.
-
Review the research and development process of "Miracle Drug T-DXd (DS-8201)"
Time of Update: 2022-09-14
The T-DXd is arguably the most successful ADC in recent years. At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, after Professor Modi shared the results of the T-DXd Phase III c
-
Express activates immune cells locally in the tumor, and Roche spent $250 million to obtain innovative anti-cancer therapies
Time of Update: 2022-09-14
Good is focused on using this protein isomer technology to develop context-dependent cytokine modulation drugs to enhance the body's anti-tumor response.
Good is focused on using this protein isomer technology to develop context-dependent cytokine modulation drugs to enhance the body's anti-tumor response.
-
Professor Deng Chunhua of the 18th International Conference on Network Diseases and Prostate Disease Forum: To treat prostate diseases, we must "eat whole fish"
Time of Update: 2022-09-14
Deng Chunhua suggested that in order to achieve early diagnosis and early treatment, men should pay attention to the clues of prostate diseases from about the age of 40, and at the same time regularly check in the health examination, closely observe from the early stage of the disease, and carry out personalized integrated traditional Chinese and Western medicine treatment according to the condition, paying attention to the improvement of disease symptoms.
-
Summary: Treatment status and research progress of meningeal metastasis in non-small cell lung cancer
Time of Update: 2022-09-14
Molecularly targeted therapies and immunotherapy regimens in recent years have shown better central nervous system (CNS) permeability and are changing the treatment landscape of LM, but the prognosis of LM patients remains poor.
-
Radiology: MRI and molecular characteristics of high-grade gliomas of the thalamus in children
Time of Update: 2022-09-14
1 mutant, DMG H3 wild and enhancer homologous inhibitory protein (EZHIP) overexpression, and DMG epidermal growth factor receptor (EGFR) mutant 。 Symmetrical thalamus gliomas (bithalamus gliomas) are an independent subclass of pediatric midline tumors characterized by high frequencies and poor prognosis of other mutations in the EGRF and/or EGFR genes.
